The Government has today published more information on contingency planning for medicines supply in the event of a no deal Brexit. In response, the ABPI has highlighted the need to provide more detail, so that companies can make plans.
Patients could have access to new, ground-breaking medicines up to six months earlier and the NHS across the UK is expected to save around £930 million on its medicine bill under a new scheme being finalised between the pharmaceutical industry and the Government.
The ABPI and BIA have submitted a joint submission in response to the MHRA and DHSC consultation on 'no deal' contingency legislation for medicines and devices regulation for the UK.
The value of Scotland’s pharmaceutical industry is revealed today in a new report by the Fraser of Allander Institute which shows the significant contribution the sector makes to all parts of the Scottish economy.
This afternoon the Chancellor delivered the Budget 2018 with details of additional funding for the NHS, £1.6 billion in new investments for the modern industrial strategy and increased allocations for Brexit preparations.
World Immunisation Week is a great time to recognise the enormous contribution being made by vaccination to global health. Immunisation programmes have led to the eradication of both smallpox and rinderpest, and have seen great successes in controlling a number of infectious childhood diseases,...
The new ABPI/BHBIA Guidance notes on collecting adverse events, product complaints and special reporting situations during market research were published on 14 August 2018. The ABPI Pharmacovigilance Expert Network (PEN) have worked very closely with the British Healthcare Business Intelligence...
Parliament has voted in favour of amendment NC17 to the Trade Bill that will make it a negotiating objective for the UK Government to seek the UK's participation in the European medicines regulatory network.
The UK government have today published a White Paper detailing their position on ‘The Future Relationship between the United Kingdom and the European Union’.
A new £56 million UK innovation centre, set to revolutionise how medicines are manufactured, is to be located in Renfrewshire, Scotland, allowing the UK to capture a bigger slice of the global £98 billion small molecule pharma market.